Bright Green To Supply DEA-Approved Cannabis Extracts And Psychedelics To FDA-Registered Pharmaceutical Company
Bright Green To Supply DEA-Approved Cannabis Extracts And Psychedelics To FDA-Registered Pharmaceutical Company
Bright Green Corporation (NASDAQ:BGXX) has signed a letter of intent (LOI) to supply its DEA-approved cannabis extracts and plant-based psychedelics to Benuvia Operations, an FDA-registered, DEA-licensed and cGMP-certified leader in pharmaceutical cannabinoids and psychedelic compounds currently under investigation for clinical use.
Bright Green Corporation（纳斯达克：BGXX）已签署意向书（LOI），供应其获得DEA批准的大麻提取物和基于植物的致幻药物给Benuvia Operations，一家FDA注册、DEA许可和cGMP认证的制药类大麻素和致幻化合物领先企业，目前正接受临床应用调查。
In February, the Grants, New Mexico-based company received final approval from the New Mexico Board of Pharmacy and the DEA to register, license and authorize Schedule I and Schedule II plant-based substances and active pharmaceutical ingredients for research, production and manufacturing purposes.
今年2月，总部位于新墨西哥的公司获得了新墨西哥州药房委员会和DEA的最终批准，注册、许可和授权了计划I和计划II的植物类物质和活性药物成分，用于研究、生产和制造目的。
Under the proposed supply agreement in the LOI, Benuvia plans to utilize Bright Green's unique capability to produce Schedule I and II raw materials, fully compliant with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP) and DEA regulations. These raw materials will be used to manufacture cGMP pharmaceutical-grade Active Pharmaceutical Ingredients domestically for both U.S. and global markets.
根据意向书中的拟议供应协议，Benuvia计划利用Bright Green独特的能力生产计划I和计划II原料，完全符合良好农业和采集规范（GACP），良好生产规范（GMP）和DEA法规。这些原料将用于国内制造cGMP药品级活性药物成分，供应美国和全球市场。
Read Also: LSD's Potential In Pain Management: New Research Sheds Light On Psychedelic's Influence On Brain Networks
阅读还需：LSD在疼痛管理中的潜力：新研究揭示了致幻药对大脑网络的影响
Schedule I substances include cannabis, psilocybin, mescaline, peyote and ibogaine. Schedule II substances include various forms of opium, such as raw opium, poppy straw, opium extracts, powdered opium, granulated opium, opium tincture, opium fluid extracts and opium straw concentrates, as well as erythroxylon coca (cocaine).
计划I物质包括大麻、蘑菇素、麦斯卡林、佩约特和伊波美。计划II物质包括各种鸦片制剂，如生鸦片、罂粟秆、鸦片提取物、鸦片粉、鸦片颗粒、鸦片口服液、鸦片流体提取物和鸦片秆浓缩物，还包括古柯碱。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 免费订阅我们的新闻简报以获得Benzinga对大麻行业和市场的独家分析和头条新闻。如果你对这个行业很认真，不能错过。
Bright Green sees this as yet another step towards becoming the leading domestic supplier of DEA-controlled, plant-based raw materials to produce cannabinoid, psychedelic and opioid-based drugs in the USA. With a new round of fundraising and supply agreements in the works, the company says it is positioned for a strong performance in 2025.
Bright Green认为这是朝着成为美国领先的国内供应商迈出的又一步，供应受DEA控制的植物类原料，用于制造大麻素、致幻物质和以鸦片为基础的药品。该公司表示，凭借新一轮的募资和供应协议，已经为2025年的强劲业绩做好了准备。
The Drug Enforcement Administration (DEA) just completed its annual operational procedures for all Schedule I and II drug cultivation and manufacturing in July. Bright Green met this national standard and is now one step closer to beginning operations and supplying the pharmaceutical world with the materials it needs to innovate.
美国缉毒局（DEA）于7月完成了对所有I类和II类药物的种植和制造的年度运营程序。Bright Green达到了这一国家标准，现在离开始运营并为药品行业提供创新所需的材料更近了一步。
Price Action
股价变动
Bright Green Corporation shares traded 2.6% higher at $0.23 per share at the time of publication.
Bright Green公司股票交易价格每股0.23美元，在发布时上涨了2.6%。
- Village Farms And TILT Holdings: A Tale Of Two Cannabis Companies Facing Diverging Fortunes
- Village Farms和TILt Holdings：两家大麻股面临不同命运的故事
Photo: Courtesy of Ryland zweifel via Shutterstock
照片：由Ryland zweifel通过Shutterstock提供的礼物